INM

At a composite of 34, InMed Pharmaceuticals scores as Underweight, with conviction of 1 out of 5 backing the assessment. Four pillars feed the composite in fixed weights (35/25/25/15 for fundamentals, regulatory, market, and editorial), and no clause of the score is hidden from the reader. Regulatory carries this profile, printing 49 and setting the ceiling on the composite. The fundamentals pillar sits at 21, and is the main drag on the composite.

Working through the numbers, InMed Pharmaceuticals shows reported revenue growth of -26.2 percent year over year, an operating margin of -162.8 percent, a market cap near 9 million, a jurisdictional posture reading of 50. Those inputs are the ones that drive the Underweight anchor rather than sentiment. The scoring pipeline pulls only from primary regulatory filings, licensed fundamentals data, institutional pricing feeds, and CIN newsroom coverage, and each pillar exposes its own inputs. This lets InMed Pharmaceuticals be lined up against the US operator peer set on identical inputs, with refresh cadence tied directly to primary-source ingest.

Filing cadence and jurisdictional posture remain the primary drivers, with regulatory contributing 49. A sustained lift in filing frequency across the trailing 90 days combined with zero enforcement events would tighten the Underweight conclusion.